Key result
The NCRP expert committee reviewed associations between radiotherapy and late adverse effects, concluding that older technologies remain relevant for current risk assessment when dose is considered.
Why the study?
What are the associations between radiotherapy and the risk of second malignant neoplasms and cardiovascular disease in cancer survivors?
Population
Cancer survivors
Design
Review
Authors
Loading...
Supports dose-informed risk assessment using historical data in survivors; leaves open late effects of newer modalities.
What are the associations between radiotherapy and the risk of second malignant neoplasms and cardiovascular disease in cancer survivors?
This NCRP review highlights the critical need for comprehensive research and risk prediction models to address the late adverse effects of radiotherapy, specifically second malignant neoplasms and cardiovascular disease, in cancer survivors.
Travis et al. (2012) conducted a review in Cancer survivors at risk for second malignant neoplasms and cardiovascular disease. Radiotherapy was evaluated on Second malignant neoplasms and cardiovascular disease. The NCRP expert committee reviewed associations between radiotherapy and late adverse effects, concluding that older technologies remain relevant for current risk assessment when dose is considered.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: